tyr in Medical Technology

deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer

... being prone to freckles and sunburn. A SNP in the tyr (tyrosinase) gene on chromosome 11, previously lin...to confer susceptibility to sunburn. Both ASIP and tyr are known to play a role in pigmentation. Becaus...inants of pigmentation in Europeans' and 'ASIP and tyr pigmentation variants associate with cutaneous mel...

Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharma's Product Class

...t fly (Drosophila) by introducing mutations in the tyrosyl-tRNA synthetase which correspond to disease a...ome CMT patients have mutations in a gene encoding tyrosyl-tRNA synthetase. While tRNA synthetases play... Instead, in humans and this fruit fly model, the tyrosyl-tRNA synthetase gene encodes a distinct funct...

Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia

...to improve patient outcomes and the overall cost of healthcare." Developed by Cephalon scientists, lestaurtinib is a potent inhibitor of several tyrosine kinases including FLT3 and a Janus kinase (JAK2). In leukemic cells, lestaurtinib inhibits FLT3 activity and induces cell death (apoptosis). In ...

Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections

...panded indications including bacteremia, severe CAP and osteomyelitis Lower potential for drug-drug interactions including those with dietary tyramine, SSRIs and vasoconstrictors About Trius Therapeutics Trius Therapeutics is discovering and developing innovative antiba...

Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients

...ty, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in...

Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506

...hibitor) BAY 73-4506 is a dual targeted VEGFR2-TIE2 anti-angiogenic oral tyrosine kinase inhibitor (TKI) with a kinase inhibition profile targeting angiogenic, stromal and oncogenic receptor tyrosine kinases (TK). In preclinical studies, BAY 73-4506 has been shown to ...

Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009

...ta on BIBW 2992, an Irreversible, Dual EGFR / HER2 tyrosine Kinase Inhibitor, Suggests Activity in Secon...ptor (EGFR) and human epithelial receptor 2 (HER2) tyrosine kinases.(1) It is the first irreversible EGF...nted that 'activating' mutations that arise in the tyrosine kinase (TK) domain of the EGFR gene are asso...

TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry

... MONMOUTH, N.J., May 14 /PRNewswire/ -- tyrX, Inc., a leader in the commercialization of impl...t Rhythm Society 2009 Annual Scientific Sessions*, tyrX held an AIGIS Retrospective Registry (ARR) Inves... 254 1 0.4% Dr. Dan Lerner, tyrX's Chief Medical Officer, noted that "when one lo...

Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery

...KIT signals to cells to constantly grow and divide, driving the growth of GIST.(5) Glivec in GIST Glivec is a type of treatment called a tyrosine kinase inhibitor.(13) It works in GIST by targeting the KIT protein, binding to it and preventing it from sending continuous signals to the canc...

Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma

... orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, as a potential treatment for...h product in clinical development. Bruton's tyrosine kinase is the gene that is disrupted in the ... 24 #3740 A Clinical Trial of the Bruton's tyrosine Kinase (Btk) Inhibitor PCI-32765 in Naturall...

Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas

...ed States and Canadian Academy of Pathology annual meeting in Boston this week on March 9, 2009. The presentation, entitled, "An Orally Available Syk tyrosine Kinase Inhibitor Induces Apoptosis in Peripheral T-Cell Lymphomas Overexpressing Activated Syk" suggested that Syk may play a critical role in s...

Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.

...tiple cancers; an inhibitor of Factor VIIa (PCI-27483) targeting pancreatic, gastric, colon and breast cancers; a first in class inhibitor of Bruton's tyrosine kinase (Btk) (PCI-32765) currently in a Phase I clinical trial and targeting B-cell related oncology applications; a Btk inhibitor in advanced p...

Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial

... receptors 1, 2 and 3 (VEGFR1-3). It is also under investigation for its potential direct anti-tumor activity by targeting a family of proteins called tyrosine kinases, including platelet-derived growth factor receptor (PDGFR), and stem cell factor receptor (c-kit), two proteins involved in cell prolife...

Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)

...nous dosing in two previous phase 1 studies. About Trodusquemine (MSI-1436) Trodusquemine is the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), an enzyme central to controlling the function of both the leptin and insulin pathways. By inhibiting both central and pe...

EntreMed Presents Initial Clinical Results for ENMD-2076

...ty, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to Aurora A kinase and other oncogenic proteins. Aurora kinases are key regulators of mitosis (cell division), and ar...

Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia

...ith MSI-1436 via this route later this year." About Trodusquemine (MSI-1436) Trodusquemine is the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), an enzyme central to controlling the function of both the leptin and insulin pathways. By inhibiting both central and pe...

YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia

... III/IV acneiform rash, also a severe and dose-limiting side-effect observed in all of the other antibodies and with small molecules targeting the EGF tyrosine kinase signaling pathway. Unrelated to the rash, Grade III/IV radiation dermatitis is a severe toxicity reported in almost half the patients tre...

Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia

...roaches to help Ph+ CML patients achieve the best long-term outcomes," said David Epstein, President and CEO, Novartis Oncology. Tasigna is a tyrosine kinase inhibitor approved for the treatment of adult Ph+ CML patients in the chronic or accelerated phases who are resistant or intolerant to pr...

Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics

...squemine (MSI-1436) Trodusquemine is a centrally and peripherally-acting appetite suppressant and the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), an enzyme central to controlling the function of both the leptin and insulin pathways. By inhibiting PTP1B, MSI-1436 is ...

Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer

... receptors 1, 2 and 3 (VEGFR1-3). It is also under investigation for its potential direct anti-tumor activity by targeting a family of proteins called tyrosine kinases, including platelet-derived growth factor receptor (PDGFR), and stem cell factor receptor (c-kit), two proteins involved in cell prolife...

Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium

...7/NEW076LOGO ) TAK-285 and TAK-593 are receptor tyrosine kinase inhibitors. Non-clinical data suggest...tivation of AMPK pathways in cardiac cells. -- tyrosine kinase inhibitors, such as TAK-285, GW572016... a novel small molecule selective inhibitor of the tyrosine kinases for the VEGF and PDGF receptor famil...

Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA

... CM/05 -- F1-2066: Demonstration of TR-701 Efficacy in a Mouse Inhalation Anthrax Model -- F1-2067: Absence of a Pressor Response to Oral tyramine in Conscious Telemeterized Rats Treated with the Novel Oxazolidinone TR-701: Comparison to Linezolid -- F1-2068: Quality Control Par...

CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)

... the treatment of major depressive disorder (MDD). tyrima is a selective and reversible member of a nove...rial is to evaluate the antidepressant efficacy of tyrima in patients with confirmed MDD. The trial desi...ith moderate to severe MDD who will receive either tyrima or placebo for six weeks. The primary study ob...

Susan G. Komen for the Cure(R) Makes Unprecedented Research and Local Program Grants

...ing cancer investigators. Dr. Boerner's grant, titled "Transphosphorylation of the EGFR (epidermal growth factor receptor) by Met and other receptor tyrosine kinases in breast cancer," involves studying the treatment of patients with advanced breast cancer. The majority of breast cancer deaths arise f...

Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months

...Lyon, France - October 6-9). Vaxfectin(R)-formulated Cancer Vaccines In a mouse study, a Vaxfectin(R)-formulated vaccine containing a peptide from tyrosinase-Related Protein 2 (TRP-2), an antigen commonly expressed by several types of tumors including glioma and melanoma, resulted in approximately a...

Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease

...targeted therapy that has successfully treated many patients with certain rare cancers. It works by inhibiting the activity of several proteins called tyrosine kinases, such as Bcr-Abl, c-KIT and platelet-derived growth factor receptor (PDGFR), which is also thought to be involved in the progression of ...

Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting

...odusquemine (MSI-1436) Trodusquemine is a centrally and peripherally-acting appetite suppressant and the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP1B). PTP1B is central to controlling the function of both the leptin and insulin pathways. By inhibiting PTP1B, MSI-1436 is e...

Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis

...munication between the brain and other parts of the body is disrupted. The '790 patent claims "A linear random copolymer YFAK comprising amino acids tyrosine (Y), phenylalanine (F), alanine (A), and lysine (K)," )." which was licensed from Harvard University. The copolymer technology was developed in ...

Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit

...odusquemine (MSI-1436) Trodusquemine is a centrally and peripherally-acting appetite suppressant and the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP1B). PTP1B is central to controlling the function of both the leptin and insulin pathways. By inhibiting PTP1B, MSI-1436 is e...

CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study

... - State-of-the-Art PET Study Confirms tyrima Exhibits Excellent Drug-Like ...oday announced plans to advance its lead candidate tyrima(TM) into Phase II trials for the treatment of ... milestone is based on the positive results of the tyrima Phase I program reported earlier this year and...

Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma

...United States for the treatment of patients with relapsed or refractory acute promyelocytic leukemia, and CEP-701, an oral small molecule inhibitor of tyrosine kinases including FLT-3, TRK and JAK-2, in phase 3 development for acute myeloid leukemia. In Europe, Cephalon markets two additional oncology...

Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting

...ure studies." Inhibition of PTP-1B, a non-receptor isoform of the protein tyrosine phosphatase family, by MSI-1436 has been shown to reduce food intake,...ng appetite suppressant and the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP-1B). PTP-1B is central to controlling the functio...

Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma

...tastatic RCC, including immunotherapy, chemotherapy, targeted therapy, and/or radiation therapy. Some of the targeted therapies include multi-targeted tyrosine kinase inhibitors such as sunitinib (Sutent) and sorafenib (Nexavar), inhibitors of the mammalian target of rapamycin, such as temsirolimus (Tor...

Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association

...odusquemine (MSI-1436) Trodusquemine is a centrally and peripherally-acting appetite suppressant and the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP-1B). PTP-1B is central to controlling the function of both the leptin and insulin pathways. By inhibiting PTP-1B, MSI-1436 i...

Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma

...ics, Inc. (Nasdaq: PCYC ) today announced results from a preclinical study evaluating PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, in collagen induced arthritis, an established animal model for rheumatoid arthritis (RA). The data were presented during the Fed...

Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO

...ciated plasma markers calcitonin and carcinoembryonic antigen. Most of the MTC patients in the trial had previously failed other treatments, including tyrosine kinase inhibitors with anti-RET activity (e.g., vandetanib, sorafenib, motesanib), chemotherapeutics, immunotherapy, radioactive iodine, and rad...

New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens

...2 and VEGF pathways with two oral, small molecule tyrosine-kinase inhibitors (TYKERB and pazopanib) d... growth and spread of tumors are the HER family of tyrosine kinase receptors and vascular endothelial gr...RB is an oral small-molecule inhibitor of the HER2 tyrosine kinase receptor. Stimulation of HER2 is asso...

GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)

... Please also see onsite contact information listed at the end of this release. About TYKERB TYKERB is an oral small-molecule inhibitor of the HER2 tyrosine kinase receptor. Stimulation of HER2 is associated with cell proliferation and with multiple processes involved in tumor progression and metasta...

Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting

...nt recipients. Certican was first approved in the EU in 2003 and is available in more than 60 countries. Tasigna(R) (nilotinib) is a next-generation tyrosine kinase inhibitor recently approved in the US and EU as second-line therapy for patients with Philadelphia chromosome-positive chronic myeloid le...

St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity

...s into the cell. The St. Jude investigators sought to understand why T cell receptors need many copies of switch-like components called immunoreceptor tyrosine-based activation motifs (ITAMS). ITAMs are components of the CD3 adaptor proteins that attach to the T cell receptor and help transmit the contr...